| Symbol | AKTS |
|---|---|
| Name | AKTIS ONCOLOGY, INC. |
| Sector | UTILITIES |
| Region | North America |
| Industry | Telecommunications Equipment |
| Address | 9805 NORTHCROSS CENTER COURT,SUITE A, HUNTERSVILLE, North Carolina, 28078, United States |
| Telephone | +1 704 997-5735 |
| Fax | — |
| — | |
| Website | https://www.aktisoncology.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002035832 |
| Description | Akoustis is a high-tech BAW RF filter solutions company that is pioneering next-generation materials science to address the market requirements for improved RF filters - targeting higher bandwidth higher operating frequencies and higher output power compared to incumbent polycrystalline BAW technology deployed today. The Company utilizes its proprietary XBAW single-crystal BAW manufacturing process to produce bulk acoustic wave RF filters for mobile and other wireless markets which facilitate signal acquisition and accelerate band performance between the antenna and digital back end. Superior performance is driven by the significant advances of high-purity single crystal piezoelectric materials and the resonator-filter process technology which drives electro-mechanical coupling and translates to wide filter bandwidth. Additional info from NASDAQ: |
Herrmann Ken 🟡 adjusted position in 4.9K shares (2 derivative) of Aktis Oncology, Inc. (AKTS) at $24.56 Transaction Date: Jul 20, 2026 | Filing ID: 310991
Read moreHerrmann Ken 🟡 adjusted position in 3.1K shares (1 derivative) of Aktis Oncology, Inc. (AKTS) at $25.21 Transaction Date: Jul 17, 2026 | Filing ID: 309115
Read more📋 KEN HERRMANN (Director) plans to sell 5K shares of AKTIS ONCOLOGY, INC. (at $24.56 each, total $119K) Filed: Jul 20, 2026 | ID: 007234
Read more📋 KEN HERRMANN (Director) plans to sell 3K shares of AKTIS ONCOLOGY, INC. (at $25.21 each, total $77K) Filed: Jul 17, 2026 | ID: 007199
Read moreAktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Read moreNew Form SCHEDULE 13G - Aktis Oncology, Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001140361-26-021340 <b>Size:</b> 7 KB
Read more(75% Positive) AKTIS ONCOLOGY, INC. (AKTS) Reports Q2 2026 Financial Results
Read moreAktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Read more